Press ReleaseAIMHI_wpuser2024-08-29T11:16:30+00:00

Press Release

Press Release

AIM-HI Portfolio Company Profile: InterLeukin Combinatorial Therapies

AIMHI_wpuser2025-02-21T16:00:10+00:00July 22, 2020|Press Release|

Meet Rose Wang

AIMHI_wpuser2025-02-21T16:00:22+00:00July 10, 2020|Press Release|

Meet Charlie Weatherspoon

AIMHI_wpuser2025-02-21T16:00:23+00:00July 3, 2020|Press Release|

Oncoheroes Biosciences and Super Sam Foundation Walking Together for Pediatric Cancer Heroes

AIMHI_wpuser2025-02-21T16:00:23+00:00June 3, 2020|Press Release|

The Gregory Foundation for Cancer Research Joins Oncoheroes Biosciences to Defeat Childhood Cancer

AIMHI_wpuser2025-02-21T16:00:23+00:00May 26, 2020|Press Release|

First-in-Class Drug Candidate Developed Through National Foundation for Cancer Research Funding Commences International Phase IIB Liver Cancer Clinical Trial

AIMHI_wpuser2025-02-21T16:00:23+00:00May 19, 2020|Press Release|

Previous 91011 Next

AIMhi

AIM-HI Accelerator Fund is a 501(c)(3) tax-exempt nonprofit organization.

Tax ID #: 82-4322538

Address:

5515 Security Lane, Suite 1105
Rockville, MD 20852

Email:

info@aim-hiaccelerator.org

Phone:

1-800-321-CURE (2873)

what we do

Copyright © AIM-HI 2025 All Rights Reserved

AIMhi

AIM-HI Accelerator Fund is a 501(c)(3) tax-exempt nonprofit organization.

Tax ID #: 82-4322538

Copyright © AIM-HI 2025 All Rights Reserved